S. 1067 · 118th Congress · Health
Ensuring Timely Access to Generics Act of 2023
- IntroducedMar 29, 2023 Done
- CommitteeReported Jun 22, 2023 Done
- Senate floorDied Jan 3, 2025 Stopped here
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill establishes additional requirements related to citizen petitions concerning applications for generic drug or biosimilar market approval. (Citizen petitions are petitions submitted by third parties requesting that the Food and Drug Administration (FDA) take certain actions, such as requiring additional warnings on a drug.)
Under the bill, the FDA may deny a citizen petition that (1) was submitted primarily to delay the approval of the relevant application, or (2) does not on its face raise valid scientific or regulatory issues. Currently, the FDA may deny a petition as an attempt at delay only if the petition meets both of these requirements.
The bill also expressly requires a third party, before filing a lawsuit to force the FDA to set aside or prevent market approval of a generic drug or biosimilar, to first file a citizen petition with the information and arguments that form the basis of the lawsuit. A citizen petition must be filed within 60 days of when the filer knew or reasonably should have known the information that forms the basis of the petition.
Congressional Research Service · summary of “Reported to Senate” version · Jun 22, 2023
Who lobbies on it
11 organizations · 59 filings · Q1 2023–Q4 2024One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Biotechnology Innovation Organization
8 of 8 quarters
“340B Drug Discount Program ---H.R.8574: 340B Affording Care for Communities and Ensuring a Strong Safety-net Act ---S.1133: 340B Accountability Act ---Executive Order on Access to Affordable Life-Saving Medications ---Program Implementation & Oversight ---PROTECT 340B Act ---SUSTAIN 340B Act Accelerated Approval…”
-
Chamber of Commerce of the U.s.a.
7 of 8 quarters
“H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues…”
-
Pharmaceutical Research and Manufacturers of America
7 of 8 quarters
“H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 456: Fairness in Orphan Drug Exclusivity Act H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the…”
8 more organizations, every filingPROUpgrade
Organizations that named S. 1067 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.
Actions
5 actions · newest first- Jun 22, 2023Placed on Senate Legislative Calendar under General Orders. Calendar No. 107.
- Jun 22, 2023Committee on Health, Education, Labor, and Pensions. Reported by Senator Sanders with an amendment in the nature of a substitute. Without written report.
- May 11, 2023Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Mar 29, 2023Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Show all 5 actionsShow fewer
- Mar 29, 2023Introduced in Senate